Purchase this article with an account.
K. W. Tai, C. Nayar, S. Harris, R. C. Gentile, R. B. Rosen; Safety and Efficacy Assessment of Intravitreal Bevacizumab for Retinal Disorders. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2110.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Bevacizumab (Avastin) is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Wet AMD, Macular edema due to diabetic retinopathy, vascular occlusion and other retinal disorders.
Retrospective chart review recording vision change, anatomical changes (Regression of NVE, CNVM, reduction in macular thickness); central thickness changes measured by (OCT) and OCT-SLO. Ocular side effects (infection, RD, IOP rise, cataract) were also recorded.
487 eyes with retinal disorders which received intravitreal injection of bevacizumab showed slight visual acuity improvement. Ten percent of the treated eyes needed bevacizumab retreatment within 1 year. Ocular side effects (infection, RD, IOP rise, cataract) were not seen.
Evaluation of 487 eyes with retinal disorders which received intravitreal injection of bevacizumab showed that bevacizumab was well tolerated and had little to no side effect findings.
This PDF is available to Subscribers Only